Recent News

• 08.12.2026 - Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
• 08.12.2026 - Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
• 08.04.2026 - The Allogene Therapeutics Second Quarter 2026 Conference Call
• 08.04.2026 - Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
• 07.29.2026 - Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
• 07.29.2026 - Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
• 07.15.2026 - Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
• 07.15.2026 - Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
• 07.15.2026 - Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
• 05.28.2026 - Allogene Therapeutics Announces Planned CEO Succession

Recent Filings

• 08.12.2026 - S-3 Registration statement under Securities Act of 1933
• 08.12.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2026 - 8-K Current report
• 08.12.2026 - EX-99.1 EX-99.1
• 08.07.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.23.2026 - 4 Statement of changes in beneficial ownership of securities